Phase I trial of YHI-1003 plus Bortezomib and Dexamethasone
Phase 1
- Conditions
- Relapsed Multiple Myeloma previously treated with Bortezomib
- Registration Number
- JPRN-jRCT2080221706
- Lead Sponsor
- Yakult Honsha Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
(1)Patients were previously diagnosed with multiple myeloma
(2)Patients must have relapsed after their last dose of bortezomib-based therapy
(3)Patients must have received 1 to 4-myeloma therapies
(4)ECOG performance status (PS) :0-2
Exclusion Criteria
(1)Patients with uncontrolled intercurrent illness
(2)Female patients who are pregnant or lactating
(3)Patients with non-secretory multiple myeloma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method